Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
AI-DRIVEN TRANSFORMATION IN DRUG DISCOVERY AND TRANSLATIONAL MEDICINE: INNOVATIONS, CHALLENGES, AND FUTURE DIRECTIONS
0
Zitationen
3
Autoren
2026
Jahr
Abstract
Introduction: Artificial Intelligence (AI) is increasingly transforming the field of drug discovery and development. By integrating advanced computational approaches such as machine learning (ML) and deep learning (DL), AI is improving the efficiency of drug design, screening, and clinical research. This review explores the role of AI in different stages of drug development and highlights its significance in translational medicine. Materials and Methods: A systematic literature review was conducted using major scientific databases including PubMed and Scopus. Keywords such as “artificial intelligence,” “drug discovery,” “machine learning,” “clinical trials,” and “translational medicine” were used for the search. Peer-reviewed articles published between 2015 and 2025 were included. The selected studies were analyzed and categorized according to different phases of drug discovery, including molecular modelling, preclinical testing, clinical trials, and personalized medicine. Results: The findings indicate that AI significantly reduces the time and cost of drug development while improving predictive accuracy. AI techniques support molecular modeling, virtual screening, drug repurposing, biomarker discovery, and clinical trial optimization. In translational medicine, AI also contributes to personalized treatment strategies through the analysis of genomic and clinical data. However, challenges remain, including data quality issues, model interpretability, ethical concerns, and the need for appropriate regulatory frameworks. Conclusion: AI has the potential to revolutionize drug discovery and translational medicine by accelerating research, improving prediction accuracy, and enabling personalized therapies. Despite existing challenges, continued advancements in AI technologies and collaborative efforts among researchers, clinicians, and regulatory bodies will further enhance its application in healthcare and pharmaceutical innovation.
Ähnliche Arbeiten
A short history of<i>SHELX</i>
2007 · 87.149 Zit.
AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
2009 · 36.137 Zit.
[20] Processing of X-ray diffraction data collected in oscillation mode
1997 · 33.562 Zit.
A new and rapid colorimetric determination of acetylcholinesterase activity
1961 · 26.773 Zit.
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
2009 · 24.454 Zit.